Walter Energy Inc. (NYSE:WLT), Radius Health Inc. (NASDAQ:RDUS) and Lululemon Athletics Inc. (NASDAQ:LULU) made major gains this Thursday. Ending the day in the negative column are MasTec Inc. (NYSE:MTZ), SandRidge Energy Inc. (NYSE:SD) and Celladon Corp. (NASDAQ:CLDN).
For much of the past decade, Crispin Odey has been waiting for inflation to rear its ugly head. The fund manager has been positioned to take advantage of rising prices in his flagship hedge fund, the Odey European Fund, and has been trying to warn his investors about the risks of inflation through his annual Read More
Walter Energy Rebounds
Walter Energy Inc. ended the day up +17.54%, rebounding after a dismal few days. A producer and exporter of metallurgical coal, Walter Energy is a new Q3 buy for Brazilian billionaire Jorge Lemann.
Radius Health Inc. gained +10.31% this Thursday, ending the day priced at $24.60. Thomas Steyer’s Farallon Capital initiated a position in the company in the second quarter of this year and as of the third quarter holds 950,000 RDUS shares. The biopharmaceutical company has gained +58.61% over the past three months.
Lululemon Athletica surged +9.11% in the wake of its third quarter earnings report – even though its numbers weren’t stellar, nor was its holiday outlook optimistic. The athletic apparel retailer, a new Q3 buy for Ray Dalio’s Bridgewater Associates, has declined -13.67% YTD.
MasTec Inc. tumbled -10.85% today. Zacks has given the company an underperform rating, and short interest in the stock is on the rise. MasTec, an infrastructure construction company, has fallen -38.45% YTD and -18.82% over the past month. Billionaire Julian Robertson picked up 563,000 MTZ shares in Q3, giving the company a 4.57% allocation in his public equity portfolio.
SandRidge Energy posted a -9.6% loss, putting its five-day performance at -23.83%. Leon Cooperman has had a stake in the company since the fourth quarter of 2012 and as of the third quarter of this year holds 45.48 million SD shares.
Celladon Corporation fell -8.59%, dipping after what’s been a +30% month-long run. The biotech company has been one of Farallon Capital’s strongest investments of the year.